UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $27.90 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• UBS AM reduced its Halozyme stake by 32.5% in the second quarter, selling 171,559 shares and retaining 356,472 shares worth approximately $27.9 million. Despite the reduction, institutional investors and hedge funds own 97.79% of the company.
• Halozyme insiders sold 32,478 shares worth about $3.08 million during the past quarter, while analyst sentiment remained favorable: nine analysts rate the stock Buy, with an average target price of $91.20.
• Strong quarterly results supported the bullish outlook: Halozyme reported $2.28 in quarterly EPS versus consensus of $1.79, while revenue rose 47.7% year over year to $481 million. The stock opened near its 52-week high at $110.76, and the company issued fiscal 2026 EPS guidance of $8.65-$9.00.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 32.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 356,472 shares of the biopharmaceutical company's stock after selling 171,559 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.31% of Halozyme Therapeutics worth $27,901,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Horizon Investment Services LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $2,254,000. Mizuho Markets Americas LLC grew its position in Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company's stock valued at $85,382,000 after acquiring an additional 926,526 shares during the last quarter. Chase Investment Counsel Corp bought a new position in Halozyme Therapeutics in the second quarter valued at about $2,035,000. Great Lakes Advisors LLC acquired a new position in Halozyme Therapeutics during the second quarter worth about $2,821,000. Finally, Aurora Investment Counsel bought a new position in shares of Halozyme Therapeutics in the second quarter worth about $1,427,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company's stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 32,478 shares of company stock valued at $3,076,604. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on HALO. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research report on Tuesday, May 12th. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Finally, Wall Street Zen raised Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research raised its FY2026 EPS estimate to $8.24 from $7.56, above the $7.75 consensus, and increased its FY2027 estimate to $9.01 from $8.96. It also lifted estimates for Q4 2026, Q1 2027, Q4 2027, Q1 2028, and Q2 2028. The revisions reinforce expectations for continued earnings growth at Halozyme. MarketBeat Halozyme estimates
• Positive Sentiment: Analyst maintains Buy rating and raises valuation target: HC Wainwright reaffirmed its Buy rating and set a $115 price target, implying additional upside from the recent trading level. Benzinga analyst update
• Positive Sentiment: Stock reaches a new one-year high: The milestone reflects strong investor momentum and growing confidence in Halozyme’s commercial and earnings outlook. Halozyme reaches new one-year high
• Neutral Sentiment: Upcoming investor conferences: CEO Helen Torley and CFO Darren Snellgrove are scheduled to participate in conferences and meet with investors. The events could provide updates on ENHANZE and Halozyme’s broader drug-delivery portfolio, but no new financial guidance was announced. Halozyme investor conferences announcement
• Negative Sentiment: Some longer-term estimates were reduced: Zacks lowered its Q3 2027 EPS forecast to $2.16 from $2.26 and FY2028 EPS to $10.06 from $10.21. These modest cuts partially offset the broader set of upward revisions, though the estimates still imply substantial future earnings growth.

Halozyme Therapeutics Stock Up 1.0%

Halozyme Therapeutics stock opened at $110.76 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $111.15. The firm has a 50 day moving average price of $90.05 and a two-hundred day moving average price of $75.58. The firm has a market cap of $12.57 billion, a price-to-earnings ratio of 33.06, a PEG ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 EPS. The company's quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source